• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Trevi Therapeutics Inc.

    8/7/25 4:23:45 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    S-8 1 trvi-20250807.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on August 7, 2025

    Registration Statement No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     

    Trevi Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    45-0834299

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    195 Church Street, 16th Floor

    New Haven, CT 06510

    (Address of principal executive offices)

    2019 Stock Incentive Plan, as amended

    (Full title of the plan)

    Jennifer Good

    President and Chief Executive Officer

    Trevi Therapeutics, Inc.

    195 Church Street, 16th Floor

    New Haven, Connecticut 06510

    (Name and address of agent for service)

    (203) 304-2499

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

     

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    Statement of Incorporation by Reference

    This Registration Statement on Form S-8, relating to the 2019 Stock Incentive Plan of Trevi Therapeutics, Inc. (the “Registrant”), as amended (the “2019 Plan”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference (i) the contents of the Registration Statement on Form S-8, File No. 333-231260, relating to the 2012 Stock Incentive Plan, as amended, of the Registrant, the 2019 Plan, and the 2019 Employee Stock Purchase Plan of the Registrant (the “2019 ESPP”), filed by the Registrant with the Securities and Exchange Commission on May 7, 2019, (ii) the contents of the Registration Statement on Form S-8, File No. 333-237193, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on March 16, 2020, (iii) the contents of the Registration Statement on Form S-8, File No. 333-257729, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on July 7, 2021, (iv) the contents of the Registration Statement on Form S-8, File No. 333-264615, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on May 2, 2022, (v) the contents of the Registration Statement on Form S-8, File No. 333-271839, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on May 11, 2023, (vi) the contents of the Registration Statement on Form S-8, File No. 333-278101, relating to the 2019 Plan, filed by the Registrant with the Securities and Exchange Commission on March 20, 2024, and (vii) the contents of the Registration Statement on Form S-8, File No. 333-285879, relating to the 2019 Plan, filed by the Registrant with the Securities and Exchange Commission on March 18, 2025.

     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

    Number

    Description

    4.1(1)

    Restated Certificate of Incorporation of the Registrant, as amended

    4.2(2)

    Amended and Restated Bylaws of the Registrant

    5.1

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

    23.1

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)

    23.2

    Consent of Ernst & Young LLP, independent registered public accounting firm

    24.1

    Power of attorney (included on the signature pages of this registration statement)

    99.1(3)

    2019 Stock Incentive Plan

    99.2(4)

    Amendment No. 1 to 2019 Stock Incentive Plan

    107

    Filing Fee Table

    ____________

    (1)
    Previously filed with the Securities and Exchange Commission on August 10, 2023 as an Exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38886) and incorporated herein by reference.
    (2)
    Previously filed with the Securities and Exchange Commission on April 14, 2023 as an Exhibit to the Registrant’s Current Report on Form 8-K (File No. 001-38886) and incorporated herein by reference.
    (3)
    Previously filed with the Securities and Exchange Commission on April 5, 2019 as an Exhibit to the Registrant’s Registration Statement on Form S-1 (File No. 333-230745) and incorporated herein by reference.
    (4)
    Previously filed with the Securities and Exchange Commission on April 29, 2025 as Appendix A to the Registrant’s Proxy Statement on Schedule 14A (File No. 001-38886) and incorporated herein by reference.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New Haven, Connecticut, on this 7th day of August, 2025.

     

     

    Trevi Therapeutics, Inc.

    By:

    /s/ Lisa Delfini

    Name:

    Lisa Delfini

    Title:

    Chief Financial Officer

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Trevi Therapeutics, Inc., hereby severally constitute and appoint Jennifer Good and Lisa Delfini, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Trevi Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

     

    /s/ Jennifer Good

    President and Chief Executive Officer, Director

    (Principal Executive Officer)

    August 7, 2025

    Jennifer Good

     

     

     

     

    /s/ Lisa Delfini

    Chief Financial Officer

    (Principal Financial Officer)

    August 7, 2025

    Lisa Delfini

     

     

     

     

    /s/ Christopher Galletta

    Controller

    (Principal Accounting Officer)

    August 7, 2025

    Christopher Galletta

     

     

     

     

     

     

     

    /s/ David Meeker, M.D.

    Chairman of the Board

    August 7, 2025

    David Meeker, M.D.

     

     

     

     

    /s/ Dominick Colangelo

    Director

    August 7, 2025

    Dominick Colangelo

     

     

     

     

    /s/ Michael Heffernan

    Director

    August 7, 2025

    Michael Heffernan

     

     

     

     

    /s/ Edward Mathers

    Director

    August 7, 2025

    Edward Mathers

     

     

     

     

    /s/ Anne VanLent

    Director

    August 7, 2025

    Anne VanLent

     

     

     

     

     

     

     


    Get the next $TRVI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    8/21/2025$18.00Overweight
    Morgan Stanley
    7/1/2025$25.00Overweight
    Cantor Fitzgerald
    5/28/2025$21.00Buy
    H.C. Wainwright
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    8/30/2024$6.00Buy
    H.C. Wainwright
    More analyst ratings

    $TRVI
    SEC Filings

    View All

    Trevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

    8/20/25 4:31:26 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.

    SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    8/14/25 5:35:10 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Trevi Therapeutics Inc.

    S-8 - Trevi Therapeutics, Inc. (0001563880) (Filer)

    8/7/25 4:23:45 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Trevi Therapeutics with a new price target

    Morgan Stanley initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $18.00

    8/21/25 8:19:41 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Trevi Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:23:22 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $21.00

    5/28/25 9:09:46 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the

    8/7/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

    Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025.

    7/31/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Participate in Upcoming August Conferences

    NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc

    7/29/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mathers Edward T

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    6/13/25 4:09:28 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Meeker David P

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    6/13/25 4:00:18 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Vanlent Anne

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    6/13/25 4:00:19 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

    NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

    9/30/24 5:30:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

    Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d

    4/2/24 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/13/24 4:30:24 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

    SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/8/24 6:57:55 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the

    8/7/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

    Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025.

    7/31/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

    Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted change from Baseline was achieved at the 108 mg BID dose group   Patients saw a rapid reduction in 24-hour cough frequency at Week 2, the first time point measured Haduvio was generally well-tolerated at all doses; discontinuation rates due to adverse events were similar in the Haduvio and placebo groups, 5.6% and 5.0%, respectively Trevi plans to request an End-of-Phase 2 meeting with the FDA later this year and is planning to initiate the Phase 3 program in the first half of 2026 Company to hos

    6/2/25 7:00:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care